Project Grant R34DA067262
Award Date 8/15/26
Completion Date 6/30/29
Dollars Obligated $206K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute on Drug Abuse awarded the University of Washington $672,701 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to implement HIV screening and prevention in low-barrier office-based opioid treatment programs. The research will improve the HIV screening and treatment cascade among patients receiving medications for opioid use disorder at four primary care-integrated opioid treatment programs at Harborview Medical Center in Seattle. The...
- The National Institute on Drug Abuse awarded Duke University $726,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026, for development and pilot implementation of a community-partnered digital health platform to enhance HIV pre-exposure prophylaxis (PrEP) linkage and retention among people who use drugs. The project applies human-centered design to develop a tailored digital health platform and implementation protocol for long-acting injectable PrEP delivery...
- The National Institute on Drug Abuse awarded New York University $256,165 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate PREP-RISE, a multi-level photovoice intervention designed to improve pre-exposure prophylaxis (PrEP) uptake and adherence among women who inject drugs. The intervention addresses barriers to PrEP adoption by integrating targeted education during participatory photovoice sessions, building trust, and facilitating warm...
- The National Institute on Drug Abuse awarded Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) $1,177,338 on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to test and expand the Street Prep intervention, a low-barrier HIV pre-exposure prophylaxis delivery model for people who use drugs and experience homelessness in San Francisco. The project conducts a Type 2 hybrid effectiveness-implementation randomized trial enrolling 150...
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $2,066,706 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test systems for integrating pre-exposure prophylaxis (PrEP) prescriptions into hospital inpatient workflows as a HIV prevention strategy for people who use drugs. The award funds PREP-TALK, a project that addresses the gap between the proven efficacy of PrEP and its confinement to outpatient settings, where...
- The National Institute of Mental Health awarded the University of Washington $729,551 on May 4, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate pharmacy-based HIV pre-exposure prophylaxis (PrEP) services, training, and financial models. The project addresses barriers to PrEP access by expanding pharmacists' capacity to prescribe and dispense PrEP independently, overcoming clinic distance and stigma that limit treatment uptake and continuity. Three...
- The National Institute on Drug Abuse awarded the University of Washington $668,939 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a hybrid type I effectiveness-implementation study testing the MIAPP (mHealth Incentivized Adherence Plus Patient Navigation) intervention for improving treatment linkage and medication adherence in patients initiated on buprenorphine in the hospital. The intervention combines financial incentives for medication...
- The National Institute on Drug Abuse awarded the University of Connecticut $755,118 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a multilevel mixed-methods longitudinal study identifying behavioral and sociocultural drivers of premature PrEP discontinuation among men aged 18–35, with explicit focus on both oral and injectable PrEP formulations and substance use populations. The study addresses a gap the CDC has identified: individuals who...
- The National Institute on Drug Abuse awarded Albert Einstein College of Medicine $756,000 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct formative research on improving pre-exposure prophylaxis (PrEP) engagement among hospitalized people who use substances through addiction consult services. The project, executed through March 2029 in Bronx, New York, comprises three research aims. First, semi-structured interviews with twenty hospitalized people...
- The National Institute on Drug Abuse awarded the University of Miami $677,248 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled trial testing the Comprehensive Tele-Health Concierge (C-THR) model, a peer-driven telehealth intervention designed to improve HIV pre-exposure prophylaxis (PrEP) initiation and retention among people with drug use histories exiting county jails. The award funds three primary research aims:...